Cymab ApS: Financial statements 2024
CVR: 39859173
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Cymab ApS (CVR 39859173) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -1,951,697 and a net result of DKK -4,627,624 compared with DKK -2,580,789 the year before. Equity in the 2024 report amounted to DKK -12,651,454. The company had 3 employees in the financial year.
- Gross Profit
- DKK -1,951,697
- Profit/Loss
- DKK -4,627,624
- Equity
- DKK -12,651,454
- Total Assets
- DKK 12,611,260
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -2M | -4.6M | -12.7M | 3 |
| 2023 | - | -1.2M | -2.6M | -8M | 2 |
| 2022 | 0 | -1.2M | -1.5M | -5.4M | 2 |
| 2021 | - | -567K | -943K | -3.9M | 1 |
| 2020 | 0 | -1.1M | -956K | -3M | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Cymab ApS has published its annual report for 2023. Gross profit came to DKK -1,206,027, and the net result was DKK -2,580,789.
As of June 24, 2024, Anne Reker Cordt has joined the board of directors of Cymab ApS.
As of June 24, 2024, Anne Reker Cordt is registered as director of Cymab ApS.
As of May 31, 2024, Stine Louise Reedtz Kjellev has stepped down as director of Cymab ApS.
About Cymab ApS
Cymab ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab ApS. The management consists of Johan Henrik Faber. The board consists of Hans Heugh Wandall (chair), Johan Henrik Faber, Mads Nikolaj Behrndt-Eriksen and Søren Erik Bjørn. The company is owned by Ebumab Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK -5,463,240 and a net result of DKK -7,576,022 compared with DKK -4,627,624 the year before. Equity in the 2025 report amounted to DKK -20,227,476.